The Federal Trade Commission (FTC) is continuing to pursue pharmaceutical manufacturers for allegedly improperly listing patents in the “Orange Book,” delaying the entry of generic drug competitors. On May 21, the FTC...more
6/3/2025
/ Antitrust Violations ,
Enforcement Actions ,
FDA Approval ,
Federal Food Drug and Cosmetic Act (FFDCA) ,
Federal Trade Commission (FTC) ,
FTC Act ,
Generic Drugs ,
Hatch-Waxman ,
Orange Book ,
Patent Litigation ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Sherman Act ,
Teva Pharmaceuticals ,
Warning Letters
Why should internet of things (IoT) manufacturers prepare to be approached by standard essential patent (SEP) holders? A recent trend suggests that many implementers may soon have to negotiate licenses that implicate...more